Atreca, Inc. in brief
Atreca, Inc. is an unlisted company in the Biotechnology industry, based in California, USA. In its latest reported year it had sales of $0 M and a net loss of $86 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Atreca, Inc.
Atreca is a Biopharmaceutical company developing novel therapeutics based on a deep understanding of the human immune response. The company annual revenue is 20.5 million USD and 130 employees as on 2020. The headquarters is in USA.
Atreca, Inc. timeline
- 2019
- 🔔· approximateInitial public offering on Frankfurt
Events of Atreca, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Atreca, Inc.
- Acquisitions and changes
- No longer listed: it is not in the SEC's, Nasdaq Trader's and FINRA's lists of US-traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #2,546 (Jan 2020) · #2,592 (Jan 2021) · #4,423 (Jan 2022) · #4,992 (Dec 2022) · #4,920 (Jul 2023) · #4,630 (Jan 2024)
Annual results
- Revenue
- $0 M
- Operating income
- —
- Net income
- $-86 M
H-1B hiring at Atreca, Inc.#
1 labor condition applications certified in fiscal 2023 for 1 positions, at a median wage of $80 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Research Associate, Target BiochemistryMolecular and Cellular Biologists | 1 | $80 K |
Where: San Carlos, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2023 | 1 | 1 | $80 K | 2 |
| FY2022 | 1 | 1 | $150 K | 1 |
| FY2021 | 5 | 5 | $110 K | 6 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Atreca, Inc.
How Atreca, Inc. compares in Biotechnology
- Revenue$0 M · higher than 0% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Atreca, Inc.🇺🇸 | $5 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Profile updated:
- Nov 14, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Atreca, Inc.? Verify and update this profile — free
Show Atreca, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.